Akorn, Inc. (NASDAQ:AKRX) Files An 8-K Regulation FD Disclosure

Akorn, Inc. (NASDAQ:AKRX) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

Story continues below

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. See attached exhibit index.


AKORN INC Exhibit
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Akorn Receives Product Approval LAKE FOREST,…
To view the full exhibit click here

About Akorn, Inc. (NASDAQ:AKRX)

Akorn Inc., together with its subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment is engaged in manufacturing and marketing generic and branded prescription pharmaceuticals, including ophthalmics, injectables, oral liquids, otics, topical, inhalants and nasal sprays. The Consumer Health segment is engaged in manufacturing and marketing branded and private-label animal health and OTC products. The Company’s Akorn Consumer Health division (ACH) markets a portfolio of OTC brands and various formulations of private-label OTC pharmaceutical products. Its OTC brand is TheraTears Therapy for Your Eyes, which is a family of therapeutic eye care products.

An ad to help with our costs